One in 18 men and women will be diagnosed with colorectal cancer during their lifetimes -- that translates into more than 150,000 people diagnosed and more than 52,000 colorectal cancer deaths each year, securing the disease as the second leading cause of cancer death in the United States.

Fortunately, mortality rates for this disease have been declining due to earlier screenings, awareness of symptoms, removal of polyps, and improved treatments through advances in research discoveries -- like today's genetic breakthroughs.

In a recent study, researchers identified a cell pathway critical in the development of colon cancer and also lung and stomach cancers.

STAT3 (signal transducer and activator of transcription 3) is the newest discovery and is a target regulated by PRPRT (receptor protein tyrosine phosphatase T), already identified to be mutated in these cancers.

"The role of protein tyrosine phosphatase in cancer is still an under-explored area," says Zhenghe John Wang, Ph.D., Assistant Professor, Department of Genetics at Case Western Reserve University School of Medicine and Case Comprehensive Cancer Center.

"Our study shows that receptor protein tyrosine phosphatase T regulates an important signaling pathway that is critical in cancer development. This identification will allow new approaches to pharmacological designs and facilitate alternative approaches for cancer treatment."

This study, published in the Proceedings of the National Academy of Sciences (PNAS Online Edition Feb. 20-23, 2007), provides new hope for the development of drugs that will target this potentially deadly disease.

Wyeth officials say their hormone replacement therapy Prempro is not the cause of one Ohio woman's breast cancer. But two jury decisions prove otherwise.

The first jury, in October, awarded Jennie Nelson and her husband $1.5 million in compensatory damages, validating Nelson's claim that her breast cancer -- resulting in a double mastectomy, chemotherapy, and radiation -- was caused by the Prempro she took for six years. When this verdict was thrown out due to a mistrial, a retrial began.

The retrial concluded yesterday -- with a Philadelphia jury awarding the Nelsons this time with $3 million.

"Both times this case has been heard on terms established by Wyeth and still the juries have clearly found that Prempro causes breast cancer," says Nelson's attorney Tobias Millrood, adding that Wyeth puts sales ahead of patient safety.

Wyeth respectfully disagrees and argues that it acted responsibly in the promotion of its hormone replacement products and in disclosing with doctors and patients all therapy-associated health risks.

Millions of women have used Wyeth's hormone replacement therapies to control the effects of menopause, and the company, sanctioned in January to pay $1 million to an Arkansas breast cancer survivor, now faces more than 5,000 lawsuits of this same nature.

Despite a large-scale study revealing drugs like Prempro increase the risk of breast cancer if used for five years or more, the drug still remains on the market. And Wyeth is so sure their drug is not at fault for causing Nelson's breast cancer that they plan to appeal yesterday's verdict.

I never predicted counseling would be part of my treatment for cancer. I am well-acquainted with the practice of talk therapy -- I have a graduate degree in counselor education and spent seven years counseling college students with presenting issues such as roommate conflicts, alcohol use and abuse, sexual assault, and depression -- but I never envisioned myself on the receiving end of such a relationship, never imagined I would be the one prescribed an anti-depressant and referred for cognitive-behavioral therapy.

Yet I have spent the past two years talking candidly -- and at times weeping uncontrollably -- with a talented young woman who has given me the tools to cope with life in the aftermath of a cancer diagnosis. And on Tuesday, the culmination of these two years will result in one final session. Together, my counselor and I will recount what has happened to me, how I have handled it, how I will proceed for the rest of my life.

At the end of my one-hour session on Tuesday, I will be set free. I will walk the white, sterile halls of a hospital basement, travel in an elevator up one flight, and exit a building I never knew could become so familiar. I will allow the outdoors to greet me, and for the very first time since cancer invaded my life, I will accept the challenge of living forward -- without the therapy that helped save my life.

On Tuesday, my case will be closed. On Tuesday, a new version of my life begins.

The bikini turns 60 this month and makes news not just for its birthday but also for its new feature -- a built-in alarm to warn wearers to get out of the sun. Not all bikinis will talk -- but those made by Canadian company Solestrom will. Solestrom has created a new bikini that goes on sale next month with a UV meter built into its belt and an alarm that sounds when it's time to seek shade. The meter on the $190 bikini displays a level of UV intensity on a scale from 0 to 20. Three to five is moderate strength, eight to 10 is very high, and anything above 11 is extreme. A person's sensitivity to UV depends mainly on skin type so this scale operates in general terms.

Despite increasing awareness of the sun's dangers, sales remain strong for the bikini. So Solestrom developed this suit to ease some of the worries about the sun's damaging rays. They have already been met with high demand from Australia and South Africa -- where skin cancer rates are highest. The United States -- now in the loop too -- has about 1 million new skin cancer cases each year.